SomaLogic joins UK Dementias Research Platform

SomaLogic joins UK Dementias Research Platform



SomaLogic announced today that is a launch partner of the Medical Research Council’s (MRC) UK Dementias Research Platform (UKDP), a £16 million ($27 million) public-private partnership set up to speed up research into dementias. According to the MRC’s press release, the collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease, by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

The UKDP brings together both industry expertise and investigator teams from eight  universities, and teams them with what will be the world’s largest group of participants in dementias research (more than two million people). The Platform will investigate the causes of dementia across a range of different neurodegenerative conditions, such as Alzheimer’s, Parkinson’s and motor neurone disease.

The Platform has attracted industry partners from both within the UK and abroad: Araclon; MedImmune, the global biologics research & development arm of AstraZeneca; GSK; IXICO; Janssen Research & Development in collaboration with Johnson & Johnson Innovation; and SomaLogic. The academic partners are: Cardiff University (academic lead), University of Cambridge, University of Edinburgh, Imperial College London, Newcastle University, University of Oxford, Swansea University and University College London.

More information about the Platform can be found on the MRC website.